title: CARs in the Lead Against Multiple Myeloma.
abstract: The recent clinical success of CD19-directed chimeric antigen receptor (CAR) T cell therapy in chronic and acute leukemia has led to increased interest in broadening this technology to other hematological malignancies and solid tumors. Now, advances are being made using CAR T cell technology to target myeloma antigens such as B cell maturation antigen (BCMA), CD138, and kappa-light chain as well as CD19 on putative myeloma stem cells. To date, only a limited number of multiple myeloma patients have received CAR T cell therapy but preliminary results have been encouraging. In this review, we summarize the recently reported results of clinical trials conducted utilizing CAR T cell therapy in multiple myeloma (MM).
authors.affiliation: Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, 149 13th Street, Charlestown, MA, 02129, USA.|Harvard Medical School, Boston, MA, USA.|Department of Clinical Immunology, Odense University Hospital, Odense, Denmark.|University of Southern Denmark, Odense, Denmark.
authors.forename: Maria
authors.initials: M
authors.lastname: Ormhøj
authors.affiliation: Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, 149 13th Street, Charlestown, MA, 02129, USA.|Harvard Medical School, Boston, MA, USA.
authors.forename: Felipe
authors.initials: F
authors.lastname: Bedoya
authors.affiliation: Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, 149 13th Street, Charlestown, MA, 02129, USA.|Harvard Medical School, Boston, MA, USA.
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Frigault
authors.affiliation: Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, 149 13th Street, Charlestown, MA, 02129, USA. mvmaus@mgh.harvard.edu.|Harvard Medical School, Boston, MA, USA. mvmaus@mgh.harvard.edu.
authors.forename: Marcela V
authors.initials: MV
authors.lastname: Maus
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology* / Q000378:metabolism; D002986:Clinical Trials as Topic; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000009:adverse effects / Q000379:methods; D009101:Multiple Myeloma / Q000276:immunology* / Q000628:therapy*; D011948:Receptors, Antigen, T-Cell / Q000235:genetics* / Q000276:immunology / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D037182:T-Cell Antigen Receptor Specificity / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism*; D016896:Treatment Outcome
chemical_list: D000951:Antigens, Neoplasm; D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins
keywords: Adoptive T cell therapy; B cell maturation antigen; Chimeric antigen receptor; Clinical trials; Multiple myeloma